Agents targeting immune checkpoints, such as PD-1 receptor and its ligand PD-L1, have transformed the treatment of many solid tumors by reversing immunosuppressive TME, but adoption in sarcoma has been in slow progress. This evidence concerns the gene CD274 and sarcoma.